Last reviewed · How we verify
Lidocain
At a glance
| Generic name | Lidocain |
|---|---|
| Also known as | Unspecific sodium channel blocker, Xylocaine® Dental, Transnasal fiberoptic larnyngoscopy, Proxicam, Group L |
| Sponsor | Bayer |
| Target | 5-hydroxytryptamine receptor 3A, Potassium/sodium hyperpolarization-activated cyclic nucleotide-gated channel 4, Sodium channel protein type 10 subunit alpha |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | FDA-approved |
Approved indications
- Hemorrhoids
- Infestation by Phthirus pubis
- Infestation by Sarcoptes scabiei var hominis
- Itching of skin
- Local Anesthesia for Endotracheal Intubation
- Local Anesthesia for Ophthalmologic Procedure
- Local Anesthesia for Urethral Pain
- Local anesthesia
- Local anesthetic intrathecal block
- Minor Skin Wound Pain
- Mouth Irritation
- Neuralgia
- Pediculosis capitis
- Postherpetic neuralgia
- Premature ejaculation
- Prevent Minor Bacterial Skin Infection
- Pruritus ani
- Regional Anesthesia for Ophthalmologic Surgery
- Skin irritation
- Suppression of the Gag Reflex
Common side effects
Key clinical trials
- The Use of Lidocaine Gel Versus Subconjunctival Xylocaine Injection in Pterygium Excision (PHASE4)
- The Effect of Adding a Local Anesthetic to Transforaminal Epidural Injection in Cervical Disc Herniation. (NA)
- Transnasal Sphenopalatine Ganglion Block for Postoperative Pain and Recovery in Tonsillectomy (TONwoPA) (NA)
- Perioperative Intravenous Lidocaine in Liver Surgery (PHASE2, PHASE3)
- Percutaneous Electrical Nerve Stimulation As Alternative To Nerve Blocks In Anesthesia, Pain Medicine And Rehabilitation Of Nonspecific Chronic Pain (PHASE4)
- Compared With Different Method for Postcesarean Section Analgesia (NA)
- Lidocaine for Opioid Sparing in Vaso-occlusive Crisis of Sickle Cell Disease (PHASE3)
- WALANT Versus Local Anesthesia in Central Venous Catheter Insertion (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |